- Conditions
- Asthma
- Interventions
- GB001, Placebo
- Drug
- Lead sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Reslizumab
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis, Eosinophilic Esophagitis
- Interventions
- Not listed
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Eosinophilic Asthma
- Interventions
- KT-621, Placebo
- Drug · Other
- Lead sponsor
- Kymera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 34
- States / cities
- Lancaster, California • Long Beach, California • Northridge, California + 28 more
- Conditions
- Asthma
- Interventions
- Mepolizumab, Placebo, SOC
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Dexpramipexole Dihydrochloride
- Drug
- Lead sponsor
- Areteia Therapeutics
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Lancaster, California • Colorado Springs, Colorado + 23 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Etokimab, Placebo
- Biological · Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more
- Conditions
- Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
- Interventions
- Budesonide-albuterol, Benralizumab
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Skokie, Illinois
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
- Drug · Procedure
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 59
- States / cities
- Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
- Conditions
- Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 80 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more
- Conditions
- Eosinophilic Asthma, Asthma
- Interventions
- Dexpramipexole, Placebo
- Drug
- Lead sponsor
- Knopp Biosciences
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more
- Conditions
- Eosinophils, Asthma
- Interventions
- reslizumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Huntington Beach, California + 31 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet
- Drug
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more
- Conditions
- Asthma
- Interventions
- GSK3511294, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 41
- States / cities
- Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 99 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma
- Interventions
- Depemokimab
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Brooksville, Florida • Plantation, Florida • Kansas City, Kansas + 6 more
- Conditions
- Asthma
- Interventions
- Mepolizumab, SOC
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more
- Conditions
- Non-Eosinophilic Asthma
- Interventions
- AVTX-002, Placebo
- Drug
- Lead sponsor
- Avalo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Sacramento, California • Walnut Creek, California + 20 more
- Conditions
- Asthma
- Interventions
- Mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- San Diego, California • Oklahoma City, Oklahoma • Medford, Oregon + 1 more